Foundation Medicine
2018
$2.4B
Why
To violently address existential threats regarding generic competition and the need for precision targeting, Roche executed a strategic $2.4 billion acquisition of Foundation Medicine, the genomic profiling leader.
Impact
This strategic, targeted acquisition immediately provided Roche with an established national presence in comprehensive genomic testing, allowing it to cross-sell its complex targeted cancer drugs to the exact right patients.
Outcome
The Foundation Medicine acquisition allowed Roche to violently pivot its scrutinized corporate narrative toward high-margin precision medicine, establishing supremacy in the integrated pharmaceutical-diagnostics loop. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success.